Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension
- PMID: 8228207
- DOI: 10.1097/00004872-199308000-00010
Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension
Abstract
Objective: To compare the responses of angiotensin II (Ang II) and blood pressure to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme (ACE) inhibitor enalapril.
Subjects: Eight non-sodium-restricted patients with mild-to-moderate essential hypertension.
Design: A single-blind crossover study. Ro 42-5892 (600 mg orally, once a day) and enalapril (20 mg orally, once a day) were given for 8 days before detailed investigations were carried out.
Methods: Ambulatory blood pressure was measured directly for 24 h by the Oxford technique on three occasions. Off-treatment and on day 8 of treatment with Ro 42-5892 and with enalapril. Ang II was measured by radioimmunoassay after separation by high-performance liquid chromatography.
Results: Plasma renin activity and Ang II were lowered by 83% [95% confidence interval (CI) 61-105] and 68% (95% CI 49-87), respectively, 0.5-1 h after Ro 42-5892, but after only 3 h values had returned to baseline. Unlike this rapid and short-term suppression of Ang II, the maximal antihypertensive response to Ro 42-5892 (fall in blood pressure 12.9/9.0 mmHg) occurred only after 6 h. Blood pressure returned to baseline after 8 h. In response to enalapril, Ang II was maximally suppressed by 63% (95% CI 32-94) after 2 h and by 83% (95% CI 76-90) after 8 h. Despite early maximal Ang II suppression, the maximal antihypertensive response to enalapril occurred only after 12 h (fall in blood pressure 25.3/16.3 mmHg). With this compound a significant antihypertensive effect was still present 24 h after dosing.
Conclusions: Compared with enalapril at 20 mg once a day, repeated oral administration of a single dose of Ro 42-5892 at 600 mg caused only short-term suppression of Ang II and blood pressure. Suppression of Ang II and reduction in blood pressure were temporally dissociated, both with the ACE inhibitor and the renin inhibitor. This implies that the blood pressure lowering effect of these inhibitors is caused partly by Ang II suppression outside the circulation.
Similar articles
-
Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.Hypertension. 2002 Jan;39(1):E1-8. doi: 10.1161/hy0102.102293. Hypertension. 2002. PMID: 11799102 Clinical Trial.
-
Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.Circulation. 1995 Aug 15;92(4):825-34. doi: 10.1161/01.cir.92.4.825. Circulation. 1995. PMID: 7641363 Clinical Trial.
-
Additive effects of losartan and enalapril on blood pressure and plasma active renin.Hypertension. 1997 Feb;29(2):634-40. doi: 10.1161/01.hyp.29.2.634. Hypertension. 1997. PMID: 9040450 Clinical Trial.
-
Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.J Hypertens Suppl. 1992 Dec;10(7):S157-64. J Hypertens Suppl. 1992. PMID: 1291650 Review.
-
Nonparallel effects of renin inhibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects. An assay-related artifact.Am J Hypertens. 1991 Jul;4(7 Pt 1):602-9. doi: 10.1093/ajh/4.7.602. Am J Hypertens. 1991. PMID: 1873015 Review.
Cited by
-
Assessment of the role of the renin-angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren.Br J Pharmacol. 1996 Mar;117(5):891-901. doi: 10.1111/j.1476-5381.1996.tb15277.x. Br J Pharmacol. 1996. PMID: 8851507 Free PMC article.
-
Clinical pharmacokinetics and efficacy of renin inhibitors.Clin Pharmacokinet. 1995 Jul;29(1):6-14. doi: 10.2165/00003088-199529010-00002. Clin Pharmacokinet. 1995. PMID: 7586899 Review.
-
Renin inhibitors: cardiovascular drugs of the future?Cardiovasc Drugs Ther. 1996 Jul;10(3):309-12. doi: 10.1007/BF02627954. Cardiovasc Drugs Ther. 1996. PMID: 8877073 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous